BridgeBio Pharma, Inc. (BBIO)
Last updated: 2026-10-22 01:27:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Summary
BridgeBio Pharma, Inc. (BBIO) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $67.74, with a market capitalization of $13.28B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $52.75 to $93.42. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$13.28B | |
$68.04 | |
$93.42 | |
$4.98 | |
$67.55 | |
2.62M | |
2.44M | |
-- | |
$93.42 | |
$52.75 | |
-- | |
-- |
BridgeBio Pharma, Inc. (BBIO) Latest Closing Stock Price
BridgeBio Pharma, Inc. (BBIO) last closed at $67.55 as of 2026-10-21 23:34:00, unchanged from the previous close of $67.55.
During the latest regular trading session, BBIO traded between $4.98 and $93.42, with a volume of 2.62M shares. The closing price was near the upper end and near the middle of its 52-week range.
BridgeBio Pharma, Inc. (BBIO) 7-Day Stock Price Change
Over the past seven days, BridgeBio Pharma, Inc. (BBIO) moved from $65.75 to $67.74, representing a gain of 3.02% ($1.99).
The stock traded between $62.86 and $69.00 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 2.42 million shares, down versus the previous seven-day period, indicating lower trading activity.
BBIO 52-Week Price Position
Position in Range: 36.9%
BBIO is currently trading at $67.74, placing it 36.9% of the way from its 52-week low of $52.75 to its 52-week high of $93.42. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is BridgeBio Pharma, Inc. (BBIO)?
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. Its key drug is Attruby (acoramidis), an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
BridgeBio Pharma, Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 839 |
| Exchange | NASDAQ |
| Company Website |
How to Buy BridgeBio Pharma, Inc. (BBIO) Stock on MEXC
Eligible investors can buy real shares of BridgeBio Pharma, Inc. (BBIO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is BridgeBio Pharma, Inc. (BBIO) stock price today?
2.Is BBIO stock going up or down today?
3.What is BBIO pre-market price?
4.What is BBIO after-hours price?
5.Is BBIO stock trading now?
6.Where does BBIO sit relative to its 52-week high and low?
7.What sector is BridgeBio Pharma, Inc. in?
8.What is BridgeBio Pharma, Inc.'s market capitalization and where is it listed?
9.How is BBIO valued in terms of P/E ratio and EPS?
10.Does BridgeBio Pharma, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
BBIO Stock Calculator
Estimate the value between BBIO shares and USD.
BBIO Shares to USD
1.00 BBIO shares = 67.738 USD
Calculations are estimates based on the latest available price and are for reference only.


